Blog Posts

340B Report Publisher and CEO: Expect Congress to Act on 340B Contract Pharmacy Before Midterm Elections

Expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in his latest column for Omnicell.

After five major court decisions on the 340B contract pharmacy standoff and no quick resolution in sight, expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in

Read More »

Drug Pricing Watchdog Identifies Most Significant Price Hikes

AbbVie’s anti-inflammatory blockbuster Humira accounted for nearly $1.4 billion in additional unsupported U.S. drug spending last year, the Institute for Clinical and Economic Review says.

Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.

Read More »

340B Covered Entities: Are You Ready for the Changes to Gilead’s Advancing Access Program?

SPONSORED CONTENT

This strategy could save the 340B proceeds at your organization

Today, underinsured or uninsured patients who are undergoing treatment with a Gilead HIV treatment or preventative medication may be eligible to receive those medications at no cost through Gilead’s Advancing Access program. Under this program, covered entities are able to receive full 340B proceeds from these dispenses and can use these funds to

Read More »

News Alert: Novo Nordisk Joins Sanofi in Appealing Court’s 340B Contract Pharmacy Decision

Novo Nordisk yesterday appealed a federal district judge’s Nov. 5 joint ruling in its and fellow manufacturer Sanofi’s 340B contract pharmacy lawsuits. Sanofi appealed earlier in the day.

Drug manufacturer Novo Nordisk late yesterday appealed a federal district judge’s Nov. 5 joint ruling in its and fellow manufacturer Sanofi’s 340B contract pharmacy lawsuits. Sanofi filed its appeal earlier yesterday.

Please Login or Become a

Read More »

News Alert: Sanofi Is the Second Manufacturer to Appeal a 340B Contract Pharmacy Court Ruling

Drug manufacturer Sanofi is appealing a federal district judge’s Nov. 5 ruling in its 340B contract pharmacy lawsuit.

Drug manufacturer Sanofi today gave notice that it is appealing a federal district judge’s Nov. 5 orders and opinions in its 340B contract pharmacy lawsuit.

Please Login or Become a Paid Subscriber to View this Content

Read More »

News Alert: HRSA Sets Wheels in Motion for a New 340B Administrative Dispute Resolution Proposed Rule

HRSA has asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation.

The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation for publication in the Federal Register.

Please Login or Become a

Read More »

Appeals Court Raises Procedural Questions About Lilly’s 340B Contract Pharmacy Case

A federal appeals court is questioning whether a lower court's ruling in Lilly's 340B contract pharmacy suit is "ready for appellate review."

Drug manufacturer Lilly’s appeal of a federal district judge’s ruling late last month in the company’s 340B contract pharmacy lawsuit has hit a procedural snag.

Please Login or Become a Paid Subscriber to View this Content

Read More »

GOP Congressman Slams PBMs for Taking Away Safety Net Providers’ 340B Savings

Rep. Jake La Turner (R-Kan.) said yesterday he is concerned about PBMs "pickpocketing" health centers and other safety net providers' 340B savings.

A Kansas Republican congressman said on Capitol Hill yesterday that pharmacy benefit managers (PBMS) are taking away health centers and other safety net providers’ 340B savings and driving up their costs.

Please Login or Become a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×